Adipose tissue-derived mesenchymal stem cells (AdMSCs) represent an attractive and ethical cell source for stem cell therapy. With the recent demonstration of MSC homing properties, intravenous applications of MSCs to cell-damaged diseases have increased. In the present study, the toxicity and tumorigenicity of human AdMSCs (hAdMSCs) were investigated for clinical application. Culture-expanded hAdMSCs showed the typical appearance, immunophenotype, and differentiation capacity of MSCs, and were genetically stable at least 12 passages in culture. Cells suspended in physiological saline maintained their MSC properties in a cold storage condition for at least 3 days. To test the toxicity of hAdMSCs, different doses of hAdMSCs were injected intravenously into immunodeficient mice, and the mice were observed for 13 weeks. Even at the highest cell dose (2.5×108 cells/kg body weight), the SCID mice were viable and had no side effects. A tumorigenicity test was performed in Balb/c-nu nude mice for 26 weeks. Even at the highest cell dose (2×108 MSCs/kg), no evidence of tumor development was found. In a human clinical trial, 8 male patients who had suffered a spinal cord injury >12 months previous were intravenously administered autologous hAdMSCs (4×108 cells) one time. None of the patients developed any serious adverse events related to hAdMSC transplantation during the 3-month follow-up. In conclusion, the systemic transplantation of hAdMSCs appears to be safe and does not induce tumor development.
Get full access to this article
View all access options for this article.
References
1.
FriedensteinAJ, ChailakhjanRK, LalykinaKS. 1970. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet, 3:393–403.
2.
EricesA, CongetP, MinguellJJ. 2000. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol, 109:235–242.
3.
ZhangY, LiC, JiangX, LiH, TangP, MaoN. 2004. Comparison of mesenchymal stem cells from human placenta and bone marrow. Chin Med J, 117:882–887.
4.
ZukPA, ZhuM, MizunoH, HuangJ, FutrellJW, KatzAJ, BenhaimP, LorenzHP, HedrickMH. 2001. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng, 7:211–228.
5.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopD, HorwitzE. 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
6.
PittengerMF, MackayAM, BeckSC, JaiswalRK, DouglasR, MoscaJD, MoormanMA, SimonettiDW, CraigS, MarshakDR. 1999. Multilineage potential of adult human mesenchymal stem cells. Science (New York, N.Y.), 284:143–147.
7.
SenA, Lea-CurrieYR, SujkowskaD, FranklinDM, WilkisonWO, HalvorsenYD, GimbleJM. 2001. Adipogenic potential of human adipose derived stromal cells from multiple donors is heterogeneous. J Cell Biochem, 81:312–319.
8.
JoJY, KangSK, ChoiIS, RaJC. 2009. Comparison of neural cell differentiation of human adipose mesenchymal stem cells derived from young and old ages. Dev Reprod, 13:227–237.
9.
SaitoT, KuangJ, BittiraB, Al-KhaldiA, ChiuRCJ. 2002. Xenotransplant cardiac chimera: immune tolerance of adult stem cells. Ann Thorac Surg, 74:19–24discussion 24.
10.
MouiseddineM, FrançoisS, SemontA, SacheA, AllenetB, MathieuN, FrickJ, ThierryD, ChapelA. 2007. Human mesenchymal stem cells home specifically to radiation-injured tissues in a non-obese diabetes/severe combined immunodeficiency mouse model. Br J Radiol, 80,Spec No 1:S49–S55.
11.
GimbleJM, GuilakF, BunnellBA. 2010. Clinical and preclinical translation of cell-based therapies using adipose tissue-derived cells. Stem Cell Res Ther, 1:19.
12.
CFR - Code of Federal Regulations Title 21, 2010. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm.
13.
MaynardFM, BrackenMB, CreaseyG, DitunnoJF, DonovanWH, DuckerTB, GarberSL, MarinoRJ, StoverSL, TatorCH, WatersRL, WilbergerJE, YoungW. 1997. International standards for neurological and functional classification of spinal cord injury. American Spinal Injury Association. Spinal Cord, 35:266–274.
14.
BrimbleSN, ZengX, WeilerDA, LuoY, LiuY, LyonsIG, FreedWJ, RobinsAJ, RaoMS, SchulzTC. 2004. Karyotypic stability, genotyping, differentiation, feeder-free maintenance, and gene expression sampling in three human embryonic stem cell lines derived prior to August 9, 2001. Stem Cells Dev, 13:585–597.
15.
LangeC, CakirogluF, SpiessA, Cappallo-ObermannH, DierlammJ, ZanderAR. 2007. Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine. J Cell Physiol, 213:18–26.
16.
Meza-ZepedaLA, NoerA, DahlJA, MicciF, MyklebostO, CollasP. 2008. High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence. J Cell Mol Med, 12:553–563.
17.
LoringJF, RaoMS. 2006. Establishing standards for the characterization of human embryonic stem cell lines. Stem Cells (Dayton, Ohio), 24:145–150.
18.
Wislet-GendebienS, LeprinceP, MoonenG, RogisterB. 2003. Regulation of neural markers nestin and GFAP expression by cultivated bone marrow stromal cells. J Cell Sci, 116:3295–3302.
19.
BonabMM, AlimoghaddamK, TalebianF, GhaffariSH, GhavamzadehA, NikbinB. 2006. Aging of mesenchymal stem cell in vitro. BMC Cell Biol, 7:14.
20.
BriquetA, DuboisS, BekaertS, DolhetM, BeguinY, GothotA. 2010. Prolonged ex vivo culture of human bone marrow mesenchymal stem cells influences their supportive activity toward NOD/SCID-repopulating cells and committed progenitor cells of B lymphoid and myeloid lineages. Haematologica, 95:47–56.
21.
ImrehMP, GertowK, CedervallJ, UngerC, HolmbergK, SzökeK, CsöreghL, FriedG, DilberS, BlennowE, Ahrlund-RichterL. 2006. In vitro culture conditions favoring selection of chromosomal abnormalities in human ES cells. J Cell Biochem, 99:508–516.
22.
HansonC, CaisanderG. 2005. Human embryonic stem cells and chromosome stability. APMIS, 113:751–755.
23.
RubioD, Garcia-CastroJ, MartínMC, de la FuenteR, CigudosaJC, LloydAC, BernadA. 2005. Spontaneous human adult stem cell transformation. Cancer Res, 65:3035–3039.
24.
RubioD, GarciaS, De la CuevaT, PazMF, LloydAC, BernadA, Garcia-CastroJ. 2008. Human mesenchymal stem cell transformation is associated with a mesenchymal-epithelial transition. Exp Cell Res, 314:691–698.
25.
de la FuenteR, BernadA, Garcia-CastroJ, MartinMC, CigudosaJC. 2010. Retraction: spontaneous human adult stem cell transformation. Cancer Res, 70:6682.
26.
GarciaS, BernadA, MartínMC, CigudosaJC, Garcia-CastroJ, de la FuenteR. 2010. Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. Exp Cell Res, 316:1648–1650.
27.
RøslandGV, SvendsenA, TorsvikA, SobalaE, McCormackE, ImmervollH, MysliwietzJ, TonnJ, GoldbrunnerR, LønningPE, BjerkvigR, SchichorC. 2009. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res, 69:5331–5339.
28.
TorsvikA, RøslandGV, SvendsenA, MolvenA, ImmervollH, McCormackE, LønningPE, PrimonM, SobalaE, TonnJ, GoldbrunnerR, SchichorC, MysliwietzJ, LahTT, MotalnH, KnappskogS, BjerkvigR. 2010. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track—letter. Cancer Res, 70:6393–6396.
29.
BernardoME, ZaffaroniN, NovaraF, CometaAM, AvanziniMA, MorettaA, MontagnaD, MaccarioR, VillaR, DaidoneMG, ZuffardiO, LocatelliF. 2007. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res, 67:9142–9149.
PhilippeB, LucS, ValérieP, JérômeR, AlessandraB, LouisC. 2010. Culture and use of mesenchymal stromal cells in phase I and II clinical trials. Stem Cells Int, 2010:503593.
32.
OmoriY, HonmouO, HaradaK, SuzukiJ, HoukinK, KocsisJD. 2008. Optimization of a therapeutic protocol for intravenous injection of human mesenchymal stem cells after cerebral ischemia in adult rats. Brain Res, 1236:30–38.
33.
FurlaniD, UgurlucanM, OngL, BiebackK, PittermannE, WestienI, WangW, YerebakanC, LiW, GaebelR, LiR, VollmarB, SteinhoffG, MaN. 2009. Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy. Microvasc Res, 77:370–376.
34.
BeggsKJ, LyubimovA, BornemanJN, BartholomewA, MoseleyA, DoddsR, ArchambaultMP, SmithAK, McIntoshKR. 2006. Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons. Cell Transplant, 15:711–721.
35.
LazarusHM, HaynesworthSE, GersonSL, RosenthalNS, CaplanAI. 1995. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant, 16:557–564.
36.
HorwitzEM, GordonPL, KooWKK, MarxJC, NeelMD, McNallRY, MuulL, HofmannT. 2002. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA, 99:8932–8937.
37.
KoçON, DayJ, NiederM, GersonSL, LazarusHM, KrivitW. 2002. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH)Bone Marrow Transplant, 30:215–222.
38.
ChenS, FangW, YeF, LiuY, QianJ, ShanS, ZhangJ, ChunhuaRZ, LiaoL, LinS, SunJ. 2004. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol, 94:92–95.
39.
Le BlancK, FrassoniF, BallL, LocatelliF, RoelofsH, LewisI, LaninoE, SundbergB, BernardoME, RembergerM, DiniG, EgelerRM, BacigalupoA, FibbeW, RingdénO. 2008. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet, 371:1579–1586.
ZimmerlinL, DonnenbergAD, RubinJP, LandreneauRJ, BasseP, DonnenbergVS. 2011. Regenerative therapy and cancer: in vitro and in vivo studies of the interaction between adipose-derived stem cells and breast cancer cells from clinical isolates. Tissue Engineering Part A, 17:93–106.
42.
VilaltaM, DéganoIR, BagóJ, GouldD, SantosM, García-ArranzM, AyatsR, FusterC, ChernajovskyY, García-OlmoD, RubioN, BlancoJ. 2008. Biodistribution, long-term survival, and safety of human adipose tissue-derived mesenchymal stem cells transplanted in nude mice by high sensitivity non-invasive bioluminescence imaging. Stem Cells Dev, 17:993–1003.
43.
IzadpanahR, KaushalD, KriedtC, TsienF, PatelB, DufourJ, BunnellBA. 2008. Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res, 68:4229–4238.
44.
KirshblumS, MillisS, McKinleyW, TulskyD. 2004. Late neurologic recovery after traumatic spinal cord injury. Arch Phys Med Rehabil, 85:1811–1817.
45.
CrozierKS, GrazianiV, DitunnoJF, HerbisonGJ. 1991. Spinal cord injury: prognosis for ambulation based on sensory examination in patients who are initially motor complete. Arch Phys Med Rehabil, 72:119–121.
46.
WatersRL, AdkinsRH, YakuraJS, SieI. 1994. Motor and sensory recovery following incomplete tetraplegia. Arch Phys Med Rehabil, 75:306–311.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
